

Research Activities Newsletter

July/August 2023

In the News: Congratulations to the following awardees!!



Rachel Hageman Blair, Associate Professor of Biostatistics, is Co-PI on a new award from the National Science Foundation (PI: Zhen Wang) for the research project entitled, *PlantSynBio: Integrate Natural Product Biosynthesis into the Global Metabolic Network*. Cardiac glycosides produced by foxglove (*Digitalis lanata*) are specialized steroids for defense. The overall objective of this project is to study how the biosynthesis of cardiac glycosides interconnects with the global metabolic network. This study is expected to reveal quantitatively how carbon and electrons flow from the central metabolism to cardiac glycosides.



Saptarshi Chakraborty, Assistant Professor of Biostatistics, is Co-I on a new award from Board of Regents of the University System of Georgia on behalf of Augusta University (PI: Chelsie Armbruster, UB Microbiology and Immunology) for the research project entitled, *Metagenomic Sequencing for Improved Diagnosis of Catheter-associated Urinary Tract Infection*. This study proposes to develop best practices for extracting all microbial DNA (bacteria, fungi, parasites, viruses) from complex catheter urine specimens, building reproducible analysis pipelines to generate a quantitative analysis of the number, identity, and proportion of all microbes in the sample. The project involves aligning composition and functional capacity over time with sign and symptom onset for diagnosed and treated catheter-associated urinary tract infections (CAUTIs). The methods proposed for development will also facilitate exploration of the full microbial contribution to other common urologic conditions, which have predominantly focused on bacterial composition.



Nicholas Felicione, Assistant Professor of Community Health and Health Behavior (CHHB) is PI on a new award from UB's Center for Cannabis and Cannabinoid Research for the project entitled, *Pilot Study for Biobehavioral Ecological Momentary Assessment of Nicotine-cannabis Co-use*. This pilot project is a novel, exploratory Ecological Momentary Assessment (EMA) study that pairs behavioral and biological data to understand how behavioral patterns of consumers who used varied forms of cannabis differ by tobacco use status, and how these differences may contribute to biomarkers of drug exposure.



Akua Gyamerah, Assistant Professor of Community Health and Health Behavior (CHHB), is PI on the continuation of her K award from the National Institute of Mental Health/NIH for the project entitled, *Intersectional Minority Stress, Mental Health, and HIV Treatment and Care Among MSM Living with HIV in Ghana*. The study continues to integrate intersectionality and minority stress theory and operationalize measures to examine how intersectional social stressors affect mental health and HIV treatment outcomes among Ghanaian MSM living with HIV and to develop an intervention to mitigate factors on this pathway to improve health.



Katarzyna Kordas, Associate Professor of Epidemiology and Environmental Health (EEH), is PI on a continuation award from the National Institute of Environmental Health Sciences/NIH for the project entitled, *Effect of Complex Mixtures on Oxidative Stress and Cognition in Children*. The study continues to examine the extent to which chemical mixtures in early-middle childhood affect a molecular process thought to underlie the development of chronic disease, as well as functional endpoints that underlie children's learning and social interactions. James Olson, UB Distinguished Professor of Pharmacology & Toxicology is Co-I on the project.



Kimberly Naus, Director of CAT Clients Services, is PI on a renewal award from the NYS Office of Children and Family Services for the project entitled, *Equipment Loan Closet*. The program will continue to enable clients with visual impairments to enhance their educational and vocational goals while being provided with assistive hardware and software.



Nicole Presti, Postdoctoral trainee in the Department of Exercise and Nutrition Sciences (ENS) is PI on a new award from the Academy of Nutrition and Dietetics for the research project entitled, *The Relationship between Protein Intake and Recovery of Muscle Function after Exercise Induced Muscle Damage (EIMD) in People Following a Plant-based Diet*. This study will observe the difference in recovery of strength after EIMD in vegans and vegetarians who consume the lower and upper ends of the recommended daily protein for resistance training. **David Hostler**, Professor and Chair of Exercise and Nutrition Sciences (ENS) is Co-PI on the project.



Todd Rideout, Associate Professor of Exercise and Nutrition Sciences (ENS), is PI on a new award from the American Egg Board (MPI Xiaozhong Wen, Pediatrics) for the research project entitled, *Effects of Maternal Egg Consumption During Pregnancy and Lactation on Maternal and Child Health*. This study will address significant knowledge gaps regarding the roles of maternal egg consumption during pregnancy and lactation in both maternal and offspring health.



Gregory Wilding, Professor and former Chair of Biostatistics, is Co-I on a continuation award from the National Institute of Neurological Disorders and Stroke/NIH (PI: Ferdinand Schweser) entitled, *Deep Gray Matter Iron and Disease Progression in Multiple Sclerosis*. Work continues to determine a generalizable model of the evolution of imaging markers over time in patients relative to controls; cellular and molecular underpinnings of the imaging markers; and how imaging markers of iron are linked to neurodegeneration and injury in the white matter.

In This Issue

In the News: Congratulations to the Following Awardees	1
Grant Clinic.....	3
NIH Funding Opportunities	
Request for Applications (RFA)	6
Program Announcements Reviews in an Institute (PAR).....	11
Program Announcements.....	15
Words to Live By	16

Grant Clinic

GENERAL NOTICE

REQUESTS FOR PROPOSAL

[NOT-OD-23-142](#) – Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)

[NOT-OD-23-144](#) – Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR)

[NOT-OD-23-145](#) – Extramural Loan Repayment Program for Research in Emerging Areas Critical to Human Health (LRP-REACH)

[NOT-OD-23-146](#) – Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB)

The NIH invites qualified health professionals who contractually agree to engage in NIH mission-relevant research for an average of at least 20 hours each week for at least two years, initially, to apply for an award in the Extramural LRP. The Extramural LRP repays up to \$50,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research at a domestic, nonprofit, or government entity. Research funding from NIH is not required to participate in the Extramural LRP. LRP awards are based on an applicant's potential to build and sustain a research career. Extramural LRP applications will be accepted from September 1 until November 16, 2023.

NOTICE OF INTENT TO PUBLISH

[NOT-RM-23-018](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Community Partnerships to Advance Science for Society (ComPASS): Health Equity Research Hubs (UC2 Clinical Trial Optional)

The NIH Office of the Director, Office of Strategic Coordination intends to solicit applications for the [Community Partnerships to Advance Science for Society \(ComPASS\)](#) Health Equity Research Hubs (Hubs). The Hubs will serve as a centralized research resource, providing tailored scientific, technical, and collaborative support for sustainable community engagement, research capacity building, and training to support ComPASS community-led health equity structural intervention (CHESI) projects in collaboration with the ComPASS Coordination Center (CCC). The Hubs are one of three complementary initiatives under the ComPASS Program, which also include Community-led, Health Equity Structural Intervention projects that intervene on structural factors that create and perpetuate health inequities and the Coordination Center that provides administration, coordination, data, and research capacity-building and training support to the CHESI projects. This Notice is intended to allow applicants additional time to begin making arrangements to develop responsive applications.

[NOT-AG-23-044](#)

Notice of Intent to Publish a Funding Opportunity Announcement for High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional)

This Notice informs the research community that the National Institute on Aging (NIA) intends to issue a Request for Applications (RFA) for new and renewal applications to provide critical network support for advancing development in the following specific high-priority areas of behavioral and social research on aging: (1) Stress Measurement, (2) Life Course Health Disparities at Older Ages, (3) Aging Research on Criminal Justice and Health Disparities, (4) Rural Aging, (5) Genomics of Behavioral and Social Science, (6) Behavioral and Social Research on Aging in Animal Models.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-MH-23-200](#) – Innovative Technologies to Develop Novel Tools to Prevent and Treat HIV in Underserved Populations

The aim of this NOSI is to support the development of new technologies for the prevention or treatment of HIV, or the application of existing technologies to behavioral and social science HIV prevention or treatment research. Applicants are encouraged to focus their technological innovations on populations that are most at risk for HIV, those living with HIV who are not currently accessing HIV care or fully benefiting from antiretroviral treatment, or other populations that experience HIV health disparities. This notice applies to due dates on or after **September 5, 2023**, and subsequent receipt dates through **January 6, 2027**.

[NOT-HL-23-089](#) – Research on Barriers to Care and risk of HIV-Associated Comorbidities Among Vulnerable Population Groups

The purpose of this Notice is to inform potential applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in supporting analysis of barriers to care and risk of HIV-associated comorbidities among disproportionately vulnerable and affected population groups of people living with or at risk for HIV infection. This Notice replaces the former [NOT-HL-22-010](#). This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **May 8, 2025**.

[NOT-AI-23-046](#) – HIV Cure-Related Research in Diverse Populations

This NOSI is to highlight NIAID's interest in HIV cure-related research in diverse cohorts of people living with HIV to determine similarities and differences in the establishment and dynamics of persistent non-subtype B HIV reservoirs, as well as in post-treatment control of viremia. This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **May 7, 2026**.

[NOT-MH-23-250](#) – Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults

The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving grant applications that include developmentally tailored research focused on adolescents and young adults (youth) related to HIV prevention and treatment. This Notice of Special Interest is a reissue of [NOT-MH-20-035](#). This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **September 7, 2026**.

[NOT-MH-23-275](#) – Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets

The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving implementation research grant applications designed in partnership with domestic and global service providers to advance HIV prevention and treatment goals (domestically) or targets (globally). This NOSI is a reissue of [NOT-MH-20-024](#). This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **September 7, 2026**.

[NOT-CA-23-070](#) – Research on HIV-associated Malignancies

This is a continuation of NOT-CA-20-022, "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers, which expired on January 8, 2023. Through this NOSI, the National Cancer Institute (NCI) intends to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), which are now a leading cause of death in people with HIV (PWH). This notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **September 7, 2026**.

[NOT-DA-24-010](#) – Impacts of Psychedelic and Dissociative Drug Policy Changes on Public Health Outcomes

The purpose of this notice of special interest (NOSI) is to inform potential applicants to the National Institute on Drug Abuse ([NIDA](#)) of special interest in grant applications that examine the impact of changing state and

local psychedelic and dissociative drug policies. This notice applies to due dates on or after **October 5, 2023**, and subsequent receipt dates through **September 8, 2026**.

[NOT-AA-23-011](#) – Secondary Analyses of Existing Alcohol Research Data

The purpose of this Notice is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This NOSI encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research. This notice applies to due dates on or after **October 5, 2023**, and subsequent receipt dates through **September 6, 2026**.

[NOT-HL-23-090](#) – Advancing Research to Address the Heterogeneity of Obesity Risk, Related Health Outcomes, and Response to Treatment

This NOSI aims to increase research to understand the heterogeneity of obesity phenotypes and the underlying mechanisms that protect against or increase risk for obesity and obesity-associated conditions. The objective is to support research applications that address knowledge and portfolio gaps regarding the role of obesity in disease development. This notice applies to due dates on or after **October 5, 2023**, and subsequent receipt dates through **September 8, 2027**.

[NOT-CA-23-071](#) – Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials

The Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI) announces this Notice to encourage current grant or cooperative agreement awardees to apply for administrative supplement funds to support the development of tools and strategies to increase the participation of individuals from all population subgroups who are representative of people for whom the parent grant intervention may be indicated. DCP led or co-led programs appropriate for this opportunity include Cancer Prevention and Control Clinical Trials Grant Program, Cancer Prevention Clinical Trials Network (CP-CTNet), NCI Community Oncology Research Program (NCORP) Research Bases, NCORP Community Sites and NCORP Minority/Underserved Community Sites, Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers Program and the NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub. **Application Due Dates:** February 28, 2024; June 30, 2025; **Expiration Date:** July 1, 2025.

[NOT-MH-23-270](#) – Intersectional Stigma and Discrimination (ISD), or Other Social and Structural Determinants of Health (SSDOH) in HIV Prevention and Treatment

The purpose of this Notice is to call for research to understand and address the impact of HIV-related intersectional stigma and discrimination (ISD), or other social and structural determinants of health (SSDOH) as they relate to HIV prevention and treatment. This NOSI is a reissue of [NOT-MH-20-020](#).

[NOT-MH-23-265](#) – Mental Health Comorbidities in HIV Prevention and Treatment

The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving grant applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes. This NOSI is a reissue of [NOT-MH-20-013](#).

POLICY NOTICES

[NOT-OD-23-149](#) – The Use of Generative Artificial Intelligence Technologies is Prohibited for the NIH Peer Review Process

The purpose of this Notice is to clarify [NOT-OD-22-044](#) on Maintaining Security and Confidentiality in NIH Peer Review: Rules, Responsibilities and Possible Consequences and inform the extramural community that the NIH prohibits NIH scientific peer reviewers from using natural language processors, large language models, or other generative Artificial Intelligence (AI) technologies for analyzing and formulating peer review critiques for grant applications and R&D contract proposals. NIH is revising its Security, Confidentiality, and Non-disclosure Agreements for Peer Reviewers to clarify this prohibition. Reviewers should be aware that uploading or sharing content or original concepts from an NIH grant application, contract proposal, or critique to online generative AI tools violates the NIH peer review confidentiality and integrity requirements.

Check out this new post on the Review Matters blog at the NIH Center for Scientific Review about [Using AI in Peer Review Is a Breach of Confidentiality](#)

[NOT-OD-23-161](#) – NIH Application Instruction Updates – Data Management and Sharing (DMS) Costs

This notice updates the NIH application instructions for submitting requests for Data Management and Sharing costs in a single line item. As outlined in the [Final NIH Policy on Data Management and Sharing \(DMS\)](#), costs associated with data management and data sharing may be allowable under the budget for the proposed project. Effective for applications submitted for due dates on or after October 5, 2023, NIH will no longer require the use of the single DMS cost line item. NIH recognizes that DMS costs may be requested in many cost categories. Therefore, in line with our standard budget instructions, DMS costs must be requested in the appropriate cost category, e.g., personnel, equipment, supplies, and other expenses, following the instructions for the R&R Budget Form or PHS 398 Modular Budget Form, as applicable.

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

OCTOBER 2023 DUE DATES

[RFA-MD-24-002](#) – (R01 Clinical Trial Required)

Youth Violence Prevention Interventions

The purpose of this initiative is to support research to develop and test multilevel youth violence prevention interventions for populations that experience health disparities, and which includes strategies that address structural discrimination and other social determinants of health. **Application Due Date:** October 2, 2023; **Expiration Date:** October 3, 2023.

[RFA-CA-24-005](#) – (U01 Clinical Trial Optional)

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health

This NOFO supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the NOFO solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. **Application Due Date:** October 13, 2023; **Expiration Date:** October 14, 2023.

NOVEMBER 2023 DUE DATES

[RFA-DA-24-016](#) – (R01 R24 Clinical Trial Optional)

Patient Engagement Resource Centers to Inform SUD Treatment Services Research

This Notice invites applications to provide research resource support to the addiction services research community through the creation of Patient Engagement Resource Centers (PERCs). The goal of each PERC is to effectively engage patients (including prospective patients, families of individuals with substance use disorder [SUD], and persons in recovery) in meaningful dialogue to inform the design and interpretation of research trials and treatment services that reflect patients' needs, preferences and priorities. **Application Due Date:** November 2, 2023; **Expiration Date:** November 3, 2023.

[RFA-RM-23-015](#) – (R03 Clinical Trial Not Allowed)

Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets

This Notice of Funding Opportunity aims to promote innovative research to enhance the utility and usability of selected Common Fund data sets. The submission of small research applications is encouraged from institutions and organizations proposing projects that lead to enhanced use of selected Common Fund (<https://commonfund.nih.gov/>) data sets by the wider scientific community. **Application Date:** November 17, 2023; **Expiration Date:** November 18, 2023.

[RFA-AG-24-025](#) – (R01 Clinical Trial Optional)

Leveraging Social Networks to Promote Widespread Individual Behavior Change

This Notice is to invite basic observational or experimental behavioral and/or social science applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for health. **Application Due Date:** November

3, 2023; **Expiration Date:** November 4, 2023.

[RFA-AG-24-026](#) – (R34 Clinical Trial Optional)

Leveraging Social Networks to Promote Widespread Individual Behavior Change

This NOFO invites applications to support the planning activities necessary to develop social network interventions to promote health across the lifespan, especially in populations in which they are currently largely underdeveloped and untested (such as populations in mid- and late life). **Application Due Date:** November 3, 2023; **Expiration Date:** November 4, 2023.

[RFA-ES-23-007](#) – (P20 Clinical Trial Optional)

Exploratory Grants for Climate Change and Health Research Center Development

The purpose of this NOFO is to solicit planning grant applications for Climate Change and Health Research Centers (CCHRCs). This program will support the development of an innovative research environment to foster and sustain a transdisciplinary program of fundamental and applied research to explore the complex impacts of climate change on health and to develop action-oriented strategies that protect health and build resiliency at the individual, community, national and global levels. **Application Due Date:** November 7, 2023; **Expiration Date:** November 8, 2023.

[RFA-NS-24-025](#) – (R03 Clinical Trial Not Allowed)

Analysis of Data in the COVID-19 Neuro Databank-Biobank

The goal of this Notice is to invite applications to analyze existing data in the NINDS-supported COVID-19 Neuro Databank-Biobank (NeuroCOVID Project) to answer specific questions about neurologic symptoms, signs and sequelae of COVID-19 and the effect of COVID-19 on pre-existing neurologic conditions. This NOFO may be used to test hypotheses using existing data and may be combined with data from other United States (U.S.) and international databases for analyses. **Application Due Date:** November 8, 2023; **Expiration Date:** November 9, 2023.

[RFA-DA-24-019](#) – (R34 Clinical Trial Not Allowed)

Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA)

The purpose of this Funding Opportunity is to seek applications proposing a set of planning activities that will lay the groundwork for scientific projects aimed at using animal models and longitudinal research designs to elucidate mechanisms mediating the impact of the early-life social environment on neurobehavioral development and the risk for substance use disorders (SUD) and their comorbidities in adolescence and adulthood. **Application Due Date:** November 9, 2023; **Expiration Date:** November 10, 2023.

[RFA-DA-24-020](#) – (R01 Clinical Trials Not Allowed)

[RFA-DA-24-021](#) – (R01 Basic Experimental Studies with Humans Required)

Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders

The purpose of this NOFO is to support research project applications to expand our knowledge on the basic neurobiology of the interrelationship between sleep/circadian rhythms and substance use disorders (SUDs). These studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythms and vice-versa and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics. **Application Due Date:** November 13, 2023; **Expiration Date:** November 14, 2023.

[RFA-AA-23-001](#) – (P50 Clinical Trial Optional)

Specialized Alcohol Research Centers

The NIAAA supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol related problems, and other health related consequences across the lifespan. Topics include, but are not limited to, the nature, etiology, genetics, diagnosis, treatment, and prevention of AUD, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and minority health and NIH-designated populations that experience health disparities. **Application Due Date:** November 15, 2023; **Expiration Date:** November 16, 2023.

[RFA-AA-23-002](#) – (P60 Clinical Trial Optional)

Comprehensive Alcohol Research Centers

This Notice invites applications for Comprehensive Alcohol Research Centers which requires a dissemination core to initiate and expand community education related to the activities of the center. The purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission. These topics include, but are not limited to: the nature, etiology, genetics, epigenetics, diagnosis, epidemiology, treatment, and prevention of alcohol misuse, alcohol use disorder, alcohol-related end organ diseases and their biomedical, neurochemical, behavioral, psychosocial, and economic consequences across the lifespan and impacting racial and ethnic minority groups and other NIH-designated populations that experience health disparities.

Application Due Date: November 15, 2023; **Expiration Date:** November 16, 2023.

[RFA-CA-23-014](#) – (R21 Clinical Trial Optional)

Development of Innovation Informatics Methods and Algorithms for Cancer Research and Management

The importance of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation and that have the potential to accelerate or enhance cancer research by inviting Exploratory/Developmental Research grant applications for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum.

Application Due Date: November 17, 2023; **Expiration Date:** November 18, 2023.

[RFA-CA-23-015](#)– (U01 Clinical Trial Optional)

Early-Stage Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on early-stage development, defined here as initial tool development or the significant modification of an existing tool for a new cancer research application. The FOA encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research.

Application Due Date: November 17, 2023; **Expiration Date:** November 18, 2023.

[RFA-CA-23-016](#) – (U24 Clinical Trial Optional)

Advanced Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. **Application Due Date:** November 17, 2023; **Expiration Date:** November 18, 2023.

[RFA-CA-23-017](#) – (U24 Clinical Trial Optional)

Sustained Support for Informatics Technologies for Cancer Research and Management

This Announcement is to invite Cooperative Agreement applications for the continued development and sustainment of high-value informatics research resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Due Date:** November 17, 2023; **Expiration Date:** November 18, 2023.

[RFA-MH-24-100](#) – (R21/R33 Clinical Trial Not Allowed)

Precision HIV Health: Integrating Data and Implementation Science to Accelerate HIV Prevention and Treatment

The main objective of this NOFO is to accelerate the implementation of more targeted and sustainable interventions to improve HIV prevention, treatment, and care, which is closely aligned with the priorities of the NIMH Division of AIDS Research, the NIH Office of AIDS Research, and the U.S. Department of Health and Human Services. This NOFO aims to support phased collaborative data science and implementation science research projects that uses a multi-stage participatory simulation modeling approach to more effectively address the HIV prevention and treatment needs of the population. **Application Due Date:** November 22, 2023; **Expiration Date:** November 23, 2023.

December 2023

[RFA-OD-23-021](#) – (U01 Clinical Trial Required)

Public Health Communication Messaging about the Continuum of Risk for Tobacco Products

This Notice invites applications for a Cooperative Agreement that will utilize health communication research to better understand the impact that messaging about the continuum of risk for tobacco products may have on various segments of the population. Applications should consider effects on audiences for whom the messaging could potentially be useful (i.e., adults who use combustible products) and on those for whom the messaging could have negative consequences (e.g., youth). **Application Due Date:** December 6, 2023; **Expiration Date:** December 7, 2023.

2023 - 2025 DUE DATES

[RFA-DA-24-063](#) – (R01 Clinical Trial Not Allowed)

[RFA-DA-24-064](#) – (R21 Clinical Trial Not Allowed)

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose

The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. **Application Due Date:** February 1, 2024; **Expiration Date:** February 2, 2024.

[RFA-OD-23-013](#) – (R21 Clinical Trial Optional)

[RFA-OD-23-014](#) – (R01 Clinical Trial Optional)

Understanding Chronic Conditions Understudied Among Women

The purpose of this Funding Opportunity is to invite R21 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the [2019-2023 Trans-NIH Strategic Plan for Women's Health Research](#) "Advancing Science for the Health of Women." **Application Due Date:** June 20, 2024; **Expiration Date:** June 21, 2024.

[RFA-DA-25-001](#) – (R01 Clinical Trial Optional)

[RFA-DA-25-002](#) – (R34 Clinical Trial Required)

Addressing HIV in Highest Risk Sexual and Gender Minorities

This initiative will support epidemiologic, intervention, or implementation research that increases public health capacity to reduce the number of new HIV infections among SGM persons. This Notice requires the inclusion of major stakeholders and potential end users of research findings as collaborators; this may include individuals involved in local or state HIV program planning and, particularly for intervention research, collaborations with service delivery organizations (e.g., CBOs/ASOs, health systems, Federally Qualified Health Centers) that can implement effective interventions in their settings. **Application Due Date:** August 14, 2024; **Expiration Date:** August 15, 2024.

MULTIPLE DUE DATES

[RFA-ES-23-011](#) - _R21 Clinical Trial Not Allowed)

Time-Sensitive Research Opportunities in Environmental Health Sciences

This NOFO is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the NOFO is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. **Application Due Dates:** multiple; see announcement; **Expiration Date:** December 2, 2025.

[RFA-OD-23-017](#) – (R01 Clinical Trial Optional)

Tobacco Regulatory Science

This Notice is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Projects must address the research priorities related to the regulatory authority of the FDA Center for Tobacco Products (CTP). **Application Due Dates:** October 6, 2023; May 6, 2024; October 4, 2024; May 2, 2025.

[RFA-DA-24-037](#) – (R21 Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data

The purpose of this Announcement is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors and related disorders, prevention of substance use and HIV, and health service utilization. **Application Due Dates:** November 15, 2023; March 4, 2024; August 5, 2024; November 15, 2024.

[RFA-HG-23-017](#) – (R01 Clinical Trial Optional)

[RFA-HG-23-018](#) – (R21 Clinical Trial Optional)

Investigator-Initiated Research in Genomics and Health Equity

The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating, and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. **Application Due Dates:** November 8, 2023; July 8, 2024; July 8, 2025.

[RFA-OD-22-023](#) – (K01 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-024](#) – (K01 – Independent Clinical Trial Required)

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research is to provide support and protected time for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Application Due Dates:** November 14, 2023; July 12, 2024; March 12, 2025.

[RFA-OD-22-025](#) – (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-026](#) – (K99/R00 – Independent Clinical Trial Required)

Pathway to Independence Award in Tobacco Regulatory Research

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. **Application Due Dates:** November 14, 2023; July 12, 2024; March 12, 2025.

[RFA-DA-23-013](#) – (R01 Clinical Trial Optional)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes through Community-engaged Research

This FOA seeks to fund innovative community partnered research by diverse teams that addresses community-driven priorities for reducing disparities in outcomes for racial and ethnic minority populations related to in substance use, addiction, and related health outcomes consequences, including HIV. **Application Due Dates:** November 14, 2023; November 14, 2024.

[RFA-DA-23-061](#) – (R01 Clinical Trial Optional)

[RFA-DA-23-062](#) – (R34 Clinical Trial Optional)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations

The purpose of this FOA is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. **Application Due Dates:** November 14, 2023; November 14, 2024.

[RFA-DA-23-026](#) – (DP1 Clinical Trial Optional)

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity

This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. **Due Dates:** November 14, 2023; November 14, 2024.

[RFA-DA-23-028](#) – (R61/R33 Clinical Trial Optional)

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory

This funding announcement invites exploratory mechanistic research seeking to parse the complex effects of structural racism and investigate its impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. **Application Due Dates:** November 14, 2023; November 14, 2024.

[RFA-OD-22-028](#) – (R01 Clinical Trial Optional)

The Intersection of Sex and Gender Influences on Health and Disease

The purpose of this FOA is to invite applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#). **Application Due Dates:** November 22, 2023; November 22, 2024.

[RFA-NS-22-022](#) – (K99/R00 Independent Clinical Trial Not Allowed)

[RFA-NS-22-023](#) – (Independent Basis Experimental Studies with Humans Required)

HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAID and SUD Research

The purpose of this Announcement is to assist eligible postdoctoral researchers in research areas supported by the NIH HEAL Initiative®, with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025.

[RFA-NS-22-024](#) – (K99/R00 Independent Basic Experimental Studies with Humans Required)

[RFA-NS-22-025](#) – (K99/R00 Independent Clinical Trial Not Allowed)

HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity

The purpose of this FOA is to assist a cohort of new and talented independent investigators from diverse backgrounds (e.g. see [NOT-OD-20-031](#) Notice of NIH's Interest in Diversity) with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025.

[RFA-DA-25-019](#) (R01 Clinical Trial Required)

[RFA-DA-25-020](#) (R34 Clinical Trial Required)

Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services

The purpose of this Notice is to address research gaps in understanding how to improve health outcomes among persons who are at heightened risk for HIV or living with HIV, Hepatitis, and substance use in the US, and to inform novel strategies for integrating primary care, HIV, Hepatitis, and substance use disorder (SUD) prevention and treatment services. The NOFO will support research that promotes scalable strategies of integrated care and services designed to improve health outcomes related to HIV, Hepatitis B and C (optional) and SUD. **Application Due Dates:** August 20, 2024; March 19, 2025; **Expiration Date:** March 20, 2025.

[RFA-ES-23-004](#) – (R21 Clinical Trial Not Allowed)

Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA is intended to support research in environmental health science in which an event has or will imminently occur that provides a limited window of opportunity to collect samples and data to support the assessment of exposures and human health impact. **Due Dates:** Multiple Dates; see announcement. **Expires:** Dec. 2, 2025.

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

OCTOBER 2023 DUE DATES

[PAR-23-182](#) – (U01 Clinical Trial Not Allowed)

Accelerating Behavioral and Social Science through Ontology Development and Use: Research Network Projects

This Notice invites applications to support research projects focused on the expansion of existing or development of new ontologies for behavioral or social science research (BSSR). The research projects must include multi-disciplinary teams of subject matter experts in one or more BSSR fields, as well as ontology

related informatics and computational approaches. **Application Due Date:** October 3, 2023; **Expiration Date:** October 4, 2023

[PAR-23-174](#) – (R36 Clinical Trial Not Allowed)

Aging Research Dissertation Awards to Promote Diversity

This NOFO invites R36 applications to promote diversity in the scientific research workforce engaged in research on aging and aging-related health conditions by providing dissertation awards in all areas of research within [NIA's strategic priorities](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 17, 2024

[PAR-23-083](#) – (R61 Clinical Trial Optional)

Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline

This FOA invites research grant applications that enable the collection of *pilot data* to support early-stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. The goal of these pilot data is to serve as preliminary data for applications to the early stage and late stage clinical trial [PAR-23-081](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 19, 2024

[PAR-23-081](#) – (R01 Clinical Trial Optional)

Early and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related Cognitive Decline

This FOA invites research grant applications that enable the early- to late-stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2025

[PAR-23-177](#) – (R21 Clinical Trials Not Allowed)

Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS)

This opportunity aims to facilitate early-stage technology development that is cutting-edge with transformative potential but for which it may be difficult to secure funding. The opportunity supports early technology development projects that have a strong rationale and conceptual framework but are at the first stages where there are little to no preliminary data. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** June 20, 2025

[PAR-23-116](#) – (P30 Clinical Trial Not Allowed)

Centers for AIDS Research

The purpose of this FOA is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 5, 2025

[PAR-23-117](#) – (P30 Clinical Trial Not Allowed)

Developmental Centers for AIDS Research

The FOA is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 5, 2025

[PAR-23-269](#) – (DP1 Clinical Trial Optional)

NIDA Avant-Garde Program for IV and Substance Use Disorder Research

Applications responding to this FOA must propose projects that align with the high priority HIV/AIDS research areas as described in [NOT-OD-20-018](#). Areas of interest include innovative basic, clinical, or translational research that may lead to improved preventive interventions or therapies; creative strategies to prevent HIV transmission; novel approaches to improve outcomes of HIV and HIV-related comorbidities; innovative ideas to improve health outcomes of people with SUD and are living with HIV; and cutting-edge approaches to eradicating HIV. **Application Due Dates:** Multiple Dates; see announcement. **Expires:** August 15, 2025

[PAR-23-125](#) – (DP2 Clinical Trial Optional)

Avenir Award Program for Research on Substance Use Disorders and HIV

This Avenir program looks towards the future by supporting early-stage investigators (ESI) proposing highly innovative studies at the nexus of substance use disorders (SUD) and HIV. This FOA aims to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV. **Due Dates:** Multiple Dates; see announcement. **Expires:** August 16, 2025

[PAR-23-055](#) – (R01 Clinical Trial Not Allowed)

[PAR-23-056](#) – (R21 Clinical Trial Not Allowed)

Co-infection and Cancer

This FOA is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** *R01* – October 5, 2025; *R21* – October 16, 2025

[PAR-23-076](#) – (P50 Clinical Trial Optional)

NIDA Research Center of Excellence Grant Program

This FOA is to provide support for research Centers that (1) conduct substance use and addiction research in any area of NIDA's mission, including the intersection of substance use/addiction and HIV, (2) foster outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to relevant research communities, educational organizations, the general public, and policy makers. **Application Due Dates:** Multiple dates; see announcement. **Expiration Date:** November 19, 2025

[PAR-23-053](#) – (R61/R33 Clinical Trial Optional)

Research Infrastructure Development for Interdisciplinary Aging Studies

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. Applications should propose the development of research infrastructure to advance specific topics in aging science that require interdisciplinary partnerships or collaborations. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 3, 2025

[PAR-23-191](#) – (R21 Clinical Trial Optional)

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions

This Notice, issued by the Fogarty International Center (FIC), seeks to stimulate innovative ideas and impactful research to better understand the complexities around developing, testing, and implementing appropriate approaches for effective diagnosis, prevention, therapeutic interventions, and integrated clinical care for HIV-associated non-communicable diseases (NCDs) in Low and Middle-Income Countries (LMICs). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 9, 2025

[PAR-23-190](#) – (R01 Clinical Trial Optional)

Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries

This NOFO issued by the Fogarty International Center (FIC) seeks to support research to develop and pilot test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV and/or AIDS, and on the quality of life of People Living with HIV and/or AIDS (PLWH). The NOFO will also support interventions to address the multiple intersecting stigmas due to co-occurring diseases and/or conditions faced by PLWH. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 23, 2025

[PAR-23-064](#) – (P01 Clinical Trial Optional)

NIDA Program Project Grant Applications

NIDA seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, medications development, health services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) and associated consequences in people who use or misuse substances or have a substance use disorder, or other research areas relevant to substance use, misuse, or use disorders. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-112](#) – (R01 – Clinical Trial Optional)

Addressing the Impact of Structural racism and Discrimination on Minority Health and Health Disparities

This initiative will support intervention research that addresses structural racism and discrimination (SRD) to improve minority health or reduce health disparities. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-060](#) – (R34 Clinical Trial Optional)

Formative and Pilot Intervention research to Optimize HIV Prevention and Care Continuum Outcomes

[PAR-23-061](#) – (R21 Clinical Trial Optional)

[PAR-23-062](#) – (R01 Clinical Trial Optional)

Innovations to Optimize HIV Prevention and Care Continuum Outcomes

The NIMH invites applications for Research Project Grants that propose formative research, intervention development, and pilot-testing of interventions; formative implementation research to inform adaptation of evidence-based interventions; or development or selection of implementation strategies. Primary scientific areas of focus include the feasibility, acceptability, and safety of novel or adapted interventions that target HIV prevention or treatment, or implementation outcomes using implementation science approaches. Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-scale clinical trials or implementation science approaches should consider using the companion R01 mechanism, [PAR-23-062](#). If proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models, applications should consider the R21 mechanism ([PAR-23-061](#)). **Application Due Dates:** Multiple Dates; see announcement. **Expires:** January 10, 2026

[PAR-23-077](#) – (RM1 – Clinical Trial Optional)

Collaborative Program Grant for Multidisciplinary Teams

This Announcement encourages Collaborative Program Grant applications from institutions/organizations that propose projects addressing complex and challenging biomedical problems within the mission of NIGMS. **Application Due Dates:** Multiple Dates, see announcement. **Expiration Date:** January 28, 2026

[PAR-23-111](#) – (R21 – Clinical Trial Optional)

NIMHD Exploratory/Developmental Research Grant Program

NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-122](#) – (R01 Clinical Trial Optional)

Research with Activities Related to Diversity (ReWARD)

The goal of the NIH ReWARD program is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-152](#) – (R21 Clinical Trial Optional)

[PAR-23-153](#) – (R01 Clinical Trial Optional)

Impacts of Climate Change across the Cancer Control Continuum

This Notice aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-155](#) – (R01 Clinical Trial Required)

Understanding Expectancies in Cancer Symptom Management

This NOFO is intended to support mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAS-23-172](#) – (R34 Clinical Trials Optional)

[PAS-23-173](#) – (R01 Clinical Trials Optional)

HIV Prevention and Alcohol

The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-240](#) – (R25 Clinical Trial not Allowed)

Alcohol and Other Substance Use Research Education Programs for Health Professionals

The NIH Research Education Program supports research education activities in the mission areas of the NIH. This NOFO will support creative educational activities with a primary focus on Outreach. This is a broad category of activities that emphasizes the dissemination of biomedical, behavioral, and clinical research findings from research on alcohol and other substance use to health professionals engaged in direct patient care and clinical service delivery. **Application Due Dates:** Multiple Due Dates; see announcement. **Expiration Date:** May 26, 2026

[PAR-23-194](#) – (R36 Clinical Trials Not Allowed)

Substance Use/Substance Use Disorder Dissertation Research Award

The goal of this Notice is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Dissertation research topics should align with the National Institute on Drug Abuse (NIDA) strategic plan (<https://nida.nih.gov/about-nida/noras-blog/2022/09/nida-releases-its-2022-2026-strategic-plan>), or with the NIDA HIV/AIDS research priorities (<https://nida.nih.gov/about-nida/organization/offices/hiv-research-program-hrp/about-hiv-research-program>). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2026

[PAR-23-254](#) – (R01 Clinical Trial Not Allowed)

[PAR-23-255](#) – (R21 Clinical Trials Not Allowed)

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes

Through this NOFO, the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2026

[PAR-23-170](#) – (R01 Clinical Trial Required)

Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in Populations that Experience Health Disparities

This Notice invites applications to test cancer preventive or screening interventions to reduce the burden of cancer in populations that experience health disparities. The Office of Disease Prevention (ODP) and participating NIH Institutes, Centers, and Offices (ICs) are issuing this to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2027

NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-23-189](#)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp – Clinical Trial Not Allowed)

Submission dates vary by awarding IC. See [Table of IC-Specific Information, Requirements and Staff Contacts](#) for more details.

[PA-23-196](#)

AHRQ Health Services Research Dissertation Program (R36)

Due Dates: February 1, May 1, August 1, and November 1 annually, beginning August 1, 2023, by 5:00 PM local time of applicant organization.

Expiration Date: May 7, 2028

[PA-23-230](#)

PHS 2023-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

Expiration Date: April 6, 2024

[PA-23-231](#)

PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

Expiration Date: April 6, 2024

[PA-23-232](#)

PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

Expiration Date: April 6, 2024

[PA-23-233](#)

PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

Expiration Date: April 6, 2024

Words to Live By

"Every day may not be good, but there's something good in every day." – Author Unknown

For more information about RAS services, visit our website at sphhp.buffalo.edu/ras